A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer



Status:Completed
Conditions:Colorectal Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:10/22/2017
Start Date:January 2017
End Date:September 2017

Use our guide to learn which trials are right for you!

A Phase 1b Dose Escalation Study of the Safety and Pharmacodynamics of Brontictuzumab in Combination With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer

A Phase 1b Dose Escalation Study of the Safety and Pharmacodynamics of Brontictuzumab in
Combination with Chemotherapy for Subjects with Previously Treated Metastatic Colorectal
Cancer.

This is a phase 1b dose escalation study of the safety and pharmacodynamics of brontictuzumab
in combination with chemotherapy for subjects with previously treated metastatic colorectal
cancer. This study consists of a screening period, a treatment period and a post-treatment
follow up period in which patients will be followed for survival for up to 24 months.
Patients will be enrolled in two stages: a dose-escalation stage and an expansion phase.

Approximately 34 patients will be enrolled in this study at approximately 5 study centers in
the United States.

Inclusion Criteria:

- Histologically confirmed metastatic colorectal cancer (mCRC) previously treated with
fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF
biological therapy, and if KRAS wild-type, an anti-EGFR therapy

- ECOG performance status 0 or 1

Exclusion Criteria:

- Prior treatment with gamma secretase inhibitors or other Notch 1 inhibitors

- Subjects with known active HIV infection. Subjects with HIV that are under a stable
anti-retroviral regimen and have no evidence of immune deficiency (normal CD4 counts),
undetectable viral load, and no HIV-related infections are eligible

- Subjects with uncontrolled diarrhea <30 days prior to first administration of study
drug

- Subjects with any history of or current clinically significant gastrointestinal
disease including, but not limited to:

- Inflammatory bowel disease (including ulcerative colitis and Crohn's disease)

- Active peptic ulcer disease

- Known intraluminal metastatic lesion(s) with risk of bleeding
We found this trial at
5
sites
Sarasota, Florida
?
mi
from
Sarasota, FL
Click here to add this to my saved trials
Charleston, South Carolina
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Denver, Colorado
?
mi
from
Denver, CO
Click here to add this to my saved trials
Miami, Florida
?
mi
from
Miami, FL
Click here to add this to my saved trials
3200 West End Avenue
Nashville, Tennessee 37203
?
mi
from
Nashville, TN
Click here to add this to my saved trials